Zevra Therapeutics is dedicated to the development and commercialization of therapies for rare diseases, focusing on areas with significant unmet medical needs. The company's pipeline includes treatments for Niemann-Pick disease type C (NPC), urea cycle disorders (UCDs), and vascular Ehlers-Danlos syndrome (vEDS). Research and development efforts are centered on identifying and advancing novel therapeutic candidates, with a strong emphasis on clinical trials to evaluate safety and efficacy. Zevra's approach involves combining scientific rigor with a deep understanding of patient needs to create transformational therapies that improve the lives of individuals affected by rare diseases. The company actively collaborates with patient advocacy groups and research institutions to accelerate the development of innovative treatments and expand access to care.

Zevra Therapeutics is actively involved in the development of treatments for central nervous system (CNS) disorders, including idiopathic hypersomnia and narcolepsy. The company's research focuses on understanding the underlying mechanisms of these conditions and identifying novel therapeutic targets. Clinical trials are conducted to assess the safety and efficacy of investigational drugs, with the goal of providing patients with effective treatment options. Zevra's approach involves leveraging its expertise in drug development and collaborating with leading researchers and clinicians to advance the understanding and treatment of CNS disorders. The company is committed to improving the lives of individuals affected by these conditions by developing innovative therapies that address unmet medical needs and enhance patient outcomes. This segment includes KP1077IH and KP1077N.

Zevra Therapeutics' commercial operations encompass the marketing, sales, and distribution of its approved products, including AZSTARYS for ADHD and OLPRUVA for urea cycle disorders. The company focuses on building strong relationships with healthcare providers, patient advocacy groups, and payers to ensure broad access to its therapies. Market access strategies involve securing favorable reimbursement coverage and developing patient support programs to enhance adherence and improve outcomes. Zevra's commercial team is dedicated to providing comprehensive information and resources to healthcare professionals and patients, enabling informed treatment decisions. The company continuously monitors market trends and competitive dynamics to optimize its commercial strategies and maximize the impact of its products on patient care. This segment also includes post-market surveillance and real-world evidence generation to further support the value proposition of Zevra's therapies.